Tivicay Alternatives Compared
| Tivicay (dolutegravir) | Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | Descovy (emtricitabine / tenofovir alafenamide) |
|
|---|
| Tivicay (dolutegravir) | Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | Descovy (emtricitabine / tenofovir alafenamide) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for HIV Infection. Tivicay may also be used for purposes not listed in this medication guide. |
Prescription only
Biktarvy is a combination tablet that contains three antiviral agents which may be used to treat HIV-1 in adults and children weighing more than 25kg (55lb). It is generally well-tolerated and the... View more |
Prescription only
Prescribed for HIV Infection, Pre-Exposure Prophylaxis of HIV. Descovy may also be used for purposes not listed in this medication guide. |
||||||||||||||||||||||||
| More about Tivicay (dolutegravir) | More about Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | More about Descovy (emtricitabine / tenofovir alafenamide) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Tivicay has an average rating of 6.6 out of 10 from a total of 19 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 26% reported a negative effect. |
Biktarvy has an average rating of 7.2 out of 10 from a total of 226 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 19% reported a negative effect. |
Descovy has an average rating of 7.4 out of 10 from a total of 22 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 18% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Tivicay side effects |
View all Biktarvy side effects |
View all Descovy side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Tivicay prices |
View all Biktarvy prices |
View all Descovy prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other dolutegravir brands include: Tivicay PD |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
14 hours |
180 hours |
25.7 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 195 drugs are known to interact with Tivicay:
|
A total of 446 drugs are known to interact with Biktarvy:
|
A total of 249 drugs are known to interact with Descovy:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
August 12, 2013 |
February 07, 2018 |
April 04, 2016 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.